Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients
(European Association for the Study of the Liver) A type 2 diabetes treatment has been found to also have 'off-label' benefits for glucose control in the liver and in fatty cells known as adipose. Presented at The International Liver CongressTM 2016 in Barcelona, Spain, today, the study shows that exenatide, a treatment that targets the pancreas to improve glucose absorption, enhances glucose uptake and reduces insulin resistance in the liver and in adipose tissue.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: Alcoholism | Byetta | Diabetes | Diabetes Type 2 | Endocrinology | Fatty Liver Disease (FLD) | Infectious Diseases | Insulin | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Pancreas | Politics | Study | Urology & Nephrology